Matthias Hänel

10PUBLICATIONS
61CO-AUTHORS
Haematological tumoursHaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 18, 2026
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.

|Mar 18, 2026
Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.

Lara Bischof, Katharina Egger-Heidrich, Martin Schneider

|Jan 07, 2026
Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia.

Annaïse J Jauch, Paul Schmidt-Barbo, Christoph Schultheiss

|Jan 05, 2026
High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia.

Paul Schmidt-Barbo, Christoph Schultheiss, Annaïse J Jauch

|Nov 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

Tim Richardson, Elias Mai, Ekaterina Menis

|Mar 05, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

Sebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig

Pageof 2

Frequent Collaborators

2 joint publications

Jan-Niklas Eckardt

2 joint publications

Sebastian Stasik

2 joint publications

Christoph Röllig

2 joint publications

Tim H Brümmendorf